格隆汇12月26日丨华纳药厂(688799.SH)公布，公司以"仿制药集约化夯实根基、创新药点状突破培植潜 能"推进"仿创结合"的发展战略持续落地，基于行业发展趋势，以及自身业务发展战略布局，结合自主 研发、合作研发、投资孵化等模式，持续提升公司核心竞争力。子公司前列药业是围绕眼科用药进行布 局的产业化平台，持续深耕眼科疾病治疗领域，优化产品布局，开发具有市场前景的眼科药品。本次整 合将进一步优化公司制剂产品管线布局，充分发挥公司及子公司竞争优势，符合公司的战略规划和产业 定位，拟与前列药业进行的交易如下：（1）公司拟购买前列药业持有的注射用吲哚菁绿、荧光素钠注 射液、亚甲蓝注射液、聚多卡醇注射液（两个规格）等5个制剂项目的技术（简称"交易标的1"），交易 对价为1,010万元，资金来源于公司自有资金。（2）公司拟向前列药业出售地夸磷索钠滴眼液（两个规 格）、聚乙烯醇滴眼液、富马酸依美斯汀滴眼液等4个制剂项目的技术（简称"交易标的2"），交易对价 为700万元。 ...

格隆汇12月26日丨华纳药厂(688799.SH)公布，公司以"仿制药集约化夯实根基、创新药点状突破培植潜 能"推进"仿创结合"的发展战略持续落地，基于行业发展趋势，以及自身业务发展战略布局，结合自主 研发、合作研发、投资孵化等模式，持续提升公司核心竞争力。子公司前列药业是围绕眼科用药进行布 局的产业化平台，持续深耕眼科疾病治疗领域，优化产品布局，开发具有市场前景的眼科药品。本次整 合将进一步优化公司制剂产品管线布局，充分发挥公司及子公司竞争优势，符合公司的战略规划和产业 定位，拟与前列药业进行的交易如下：（1）公司拟购买前列药业持有的注射用吲哚菁绿、荧光素钠注 射液、亚甲蓝注射液、聚多卡醇注射液（两个规格）等5个制剂项目的技术（简称"交易标的1"），交易 对价为1,010万元，资金来源于公司自有资金。（2）公司拟向前列药业出售地夸磷索钠滴眼液（两个规 格）、聚乙烯醇滴眼液、富马酸依美斯汀滴眼液等4个制剂项目的技术（简称"交易标的2"），交易对价 为700万元。 ...

Core Viewpoint - The article discusses the emergence of Demy Pharmaceutical, a subsidiary of Kangzhe Pharmaceutical, focusing on the development and market potential of the drug "Ruxolitinib Cream" for treating vitiligo, amidst a growing demand for effective skin health products in China [1][2]. Company Overview - Demy Pharmaceutical is set to independently list in Hong Kong, having submitted its prospectus in April 2023, and is positioned to capitalize on the skin health market, which is projected to be worth billions [1][2]. - The company has a strong product pipeline, including Ruxolitinib Cream, which is the only FDA-approved JAK inhibitor for vitiligo, and other skin-related products [3][5]. Market Potential - There are over 10 million vitiligo patients in China, and the market for effective treatments is largely untapped, with Ruxolitinib Cream expected to generate significant revenue, projected at $340 million in its first full sales year [4][10]. - The skin health market is characterized by a high demand for unique and effective treatments, with Demy focusing on products that have a strong market need and limited competition [7][11]. Financial Performance - Demy Pharmaceutical has shown promising financials, with revenues expected to exceed 600 million yuan in 2024, reflecting a growth trend in the skin health segment [2][7]. - The company has maintained a positive cash flow despite not yet being profitable, indicating strong market interest and potential for future growth [2][10]. Product Pipeline - The product pipeline includes several other skin prescription drugs, with a focus on unique and differentiated products that address significant medical needs [5][7]. - The company has successfully introduced products that are the only approved treatments for specific conditions in China, enhancing its competitive edge [7][11]. Sales Strategy - Demy Pharmaceutical's sales strategy emphasizes leveraging its parent company's marketing expertise and established distribution channels, with a focus on hospital and retail pharmacy coverage [10][12]. - The company has a strong commercial team, with over 85% of its workforce dedicated to sales, which is crucial for its growth in the competitive biopharmaceutical market [10][12].